Podcast

Comparing micro-bypass implant + phaco vs phaco in POAG

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|AAO

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.



During AAO 2020, Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

See more AAO coverage

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
Related Content
SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension
November 19th 2024

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens
November 12th 2024

MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

The top 10 takeaways from AAO 2024
October 23rd 2024

The top 10 takeaways from AAO 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

© 2024 MJH Life Sciences

All rights reserved.